These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16521222)

  • 1. Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma.
    Li Y; Wo JM; Ray MB; Jones W; Su RR; Ellis S; Martin RC
    World J Gastroenterol; 2006 Feb; 12(6):928-34. PubMed ID: 16521222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
    Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
    Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
    Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
    Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
    J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.
    Sonoda R; Naomoto Y; Shirakawa Y; Fujiwara Y; Yamatsuji T; Noma K; Tanabe S; Takaoka M; Gunduz M; Tsujigiwa H; Nagatsuka H; Ohara N; Yoshino T; Takubo K; Vieth M; Tanaka N
    Histopathology; 2010 Jul; 57(1):90-100. PubMed ID: 20653782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett's esophagus.
    Majka J; Wierdak M; Szlachcic A; Magierowski M; Targosz A; Urbanczyk K; Krzysiek-Maczka G; Ptak-Belowska A; Bakalarz D; Magierowska K; Chmura A; Brzozowski T
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G375-G389. PubMed ID: 31928220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
    Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
    Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer.
    Ling FC; Baldus SE; Khochfar J; Xi H; Neiss S; Brabender J; Metzger R; Drebber U; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Histopathology; 2007 Jan; 50(2):203-9. PubMed ID: 17222248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
    Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
    World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing cyclooxygenase-2 (cox-2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl-2.
    Shimizu D; Vallböhmer D; Kuramochi H; Uchida K; Schneider S; Chandrasoma PT; Shimada H; DeMeester TR; Danenberg KD; Peters JH; DeMeester SR; Danenberg PV
    Int J Cancer; 2006 Aug; 119(4):765-70. PubMed ID: 16550596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
    Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
    Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 expression and cell proliferation are increased in MUC2-positive area of columnar-lined esophagus.
    Jang TJ; Cho MY
    Pathol Int; 2005 Sep; 55(9):546-9. PubMed ID: 16143029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase A in Barrett's carcinogenesis.
    Rugge M; Fassan M; Zaninotto G; Pizzi M; Giacomelli L; Battaglia G; Rizzetto C; Parente P; Ancona E
    Hum Pathol; 2010 Oct; 41(10):1380-6. PubMed ID: 20656315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma.
    Grotenhuis BA; van Lanschot JJ; Dinjens WN; Wijnhoven BP
    Recent Results Cancer Res; 2010; 182():39-63. PubMed ID: 20676870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?
    Fitzgerald RC
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i21-6. PubMed ID: 15711004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.